Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03612856 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
A Phase 2 study, sponsored by Aronora.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03612856 is a Phase 2 study that has completed, run by Aronora. The registered enrollment target is 27 participants.
The verdict
NCT03612856, a Phase 2 study, has completed, sponsored by Aronora.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB023 (xisomab 3G3) or placebo (at a ratio of 2:1 active: placebo).
Interventions
- DRUG placebo
- DRUG AB023- Dose 1
- DRUG AB023-Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2019-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03612856
The ClinicalTrials.gov registry entry for NCT03612856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aronora, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT03612856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03612856 about?
NCT03612856 is a clinical study titled "Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis". This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB023 (xisomab 3G3) or placebo (at a ratio of 2...
What is the current status of trial NCT03612856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-10-29. Estimated completion is 2019-07-06.
What interventions are being tested in trial NCT03612856?
The interventions under investigation include: placebo (DRUG), AB023- Dose 1 (DRUG), AB023-Dose 2 (DRUG).
Who is sponsoring clinical trial NCT03612856?
This trial is sponsored by Aronora, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.